Review
Clinical Neurology
Simona Sacco, Christian Lampl, Faisal Mohammad Amin, Mark Braschinsky, Christina Deligianni, Derya Uluduz, Jan Versijpt, Anne Ducros, Raquel Gil-Gouveia, Zaza Katsarava, Paolo Martelletti, Raffaele Ornello, Bianca Raffaelli, Deirdre M. Boucherie, Patricia Pozo-Rosich, Margarita Sanchez-del-Rio, Alexandra Sinclair, Antoinette Maassen van den Brink, Uwe Reuter
Summary: This study aims to provide a definition of triptan failure, which can quantitatively assess the efficacy of triptans in clinical practice and help explore new acute migraine treatments.
JOURNAL OF HEADACHE AND PAIN
(2022)
Article
Clinical Neurology
John H. Krege, Richard B. Lipton, Simin K. Baygani, Mika Komori, Sinead M. Ryan, Maurice Vincent
Summary: The efficacy of lasmiditan in patients with and without triptan contraindications did not differ. Lasmiditan may be a treatment option for patients with contraindications to triptans.
Article
Medicine, General & Internal
Seonkyeong Yang, Yulia Orlova, Abigale Lipe, Macy Boren, Juan M. Hincapie-Castillo, Haesuk Park, Ching-Yuan Chang, Debbie L. Wilson, Lauren Adkins, Wei-Hsuan Lo-Ciganic
Summary: The study found a significant decrease in opioid use among headache patients in US emergency departments, while there was an increasing trend in the use of acetaminophen/NSAIDs, diphenhydramine, and corticosteroids. Referrals for outpatient follow-up slightly increased over time.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Chemistry, Medicinal
Diessica Padilha Dalenogare, Camila Ritter, Fernando Roberto Antunes Bellinaso, Sabrina Qader Kudsi, Gabriele Cheiran Pereira, Maria Fernanda Pessano Fialho, Debora Denardin Luckemeyer, Caren Tatiane de David Antoniazzi, Lorenzo Landini, Juliano Ferreira, Guilherme Vargas Bochi, Sara Marchesan Oliveira, Francesco De Logu, Romina Nassini, Pierangelo Geppetti, Gabriela Trevisan
Summary: The study found that TRPA1 is involved in the development of headaches in a PMS-EAE mouse model, and the generation of TRPA1 endogenous agonists may sensitize trigeminal nociceptors to elicit PMA. This ion channel could be a potential therapeutic target for the treatment of headache in PMS patients.
Article
Clinical Neurology
Ruth Ruscheweyh, Gudrun Gossrau, Thomas Dresler, Tobias Freilinger, Stefanie Foerderreuther, Charly Gaul, Torsten Kraya, Lars Neeb, Victoria Ruschil, Andreas Straube, Joerg Scheidt, Tim Patrick Juergens
Summary: Triptans are effective for many migraine patients, but 13.1% of patients in specialized headache care in Germany have failed >= 2 triptans, showing increased migraine severity and disability associated with triptan failure. Establishing an effective and tolerable acute migraine medication is important for optimizing treatment strategies.
JOURNAL OF HEADACHE AND PAIN
(2023)
Article
Clinical Neurology
Adriana Pero, Anna Pace, Mandip S. Dhamoon
Summary: This study aimed to investigate the prevalence of triptan use among patients with migraine who have contraindications to triptan usage and the specifics of the medication prescribed. The results showed that a considerable proportion of patients with contraindications were still prescribed triptan medication.
Review
Clinical Neurology
Dilara Onan, Samaira Younis, William David Wellsgatnik, Fatemeh Farham, Saulius Andruskevicius, Ana Abashidze, Asel Jusupova, Yuriy Romanenko, Oxana Grosu, Meerimgul Zamirbekovna Moldokulova, Ulkar Mursalova, Saida Saidkhodjaeva, Paolo Martelletti, Sait Ashina
Summary: This article explores the similarities and differences in the pathophysiology, epidemiology, burden and disability, comorbidities, and responses to treatments between tension-type headache (TTH) and migraine. Distinguishing between the two in clinical practice and research is challenging due to the lack of specific diagnostic tests and biomarkers. The article also discusses future research directions to address diagnostic challenges and improve the understanding and management of these conditions.
JOURNAL OF HEADACHE AND PAIN
(2023)
Article
Multidisciplinary Sciences
Fatima Tauqeer, Mollie Wood, Sarah Hjorth, Angela Lupattelli, Hedvig Nordeng
Summary: The study found that one in four women continued to use triptan treatment during pregnancy, and those who continued had a higher demand for other acute migraine treatments.
Article
Pharmacology & Pharmacy
Marta Vila-Pueyo, Keith Page, Paul R. Murdock, Howard J. Loraine, Amanda J. Woodrooffe, Kirk W. Johnson, Peter J. Goadsby, Philip R. Holland
Summary: Lasmiditan reduces trigeminovascular activation in a preclinical model of migraine and also has a clear action in a preclinical model of cluster headache. The expression of the 5-HT1F receptor in human tissue suggests the potential utility of lasmiditan as a therapeutic option for the acute treatment of cluster headache attacks.
BRITISH JOURNAL OF PHARMACOLOGY
(2022)
Article
Clinical Neurology
Marte H. Bjork, Solveig Borkenhagen, Francisco Oteiza, Aud N. Dueland, Frank E. Sorgaard, Erik Magnus Saether, Christoffer Bugge
Summary: The study found a favorable effect of CGRPabs, amitriptyline, and simvastatin compared with beta blockers, while topiramate and clonidine were associated with poorer outcomes. Patients on simvastatin, CGRPabs, and amitriptyline were more likely to achieve a clinically significant reduction in triptan use during the first 90 days of treatment.
EUROPEAN JOURNAL OF NEUROLOGY
(2023)
Article
Clinical Neurology
Luca Giani, Alberto Proietti Cecchini, Alberto Astengo, Giuseppe Lauria, Massimo Leone
Summary: In cluster headache patients with long and frequent attacks, those who do not respond to subcutaneous sumatriptan have longer duration and more frequent attacks compared to responders.
Review
Oncology
Carolyn A. Bernstein
Summary: This review article provides a comprehensive overview of headache evaluation and treatment in cancer patients, including the diagnostic process, common types of headaches, pharmacological treatment, and complementary and integrative therapies.
Review
Clinical Neurology
Jason Charles Ray, Mahima Kapoor, Richard J. Stark, Shuu-Jiun Wang, Lars Bendtsen, Manjit Matharu, Elspeth Jane Hutton
Summary: Migraine is the second largest cause of years lost to disability globally, with limited therapeutics specifically developed for its treatment. After 30 years of research, CGRP inhibitors have emerged as a promising tool for migraine prevention. However, with limited real-world experience, the systemic actions of CGRP need to be considered for potential side effects.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
(2021)
Review
Clinical Neurology
Monica Chan, Alison Thaler
Summary: This review discusses the epidemiology, presentation, and pathophysiology of persistent post-stroke headache (PPSH), as well as the acute and preventive treatment options. The 2018 International Classification of Headache Disorders, 3rd edition (ICHD-3) includes criteria for diagnosing PPSH. Further investigation is needed to understand the burden of PPSH and to explore the efficacy and safety of potential treatment options.
CURRENT PAIN AND HEADACHE REPORTS
(2023)
Article
Clinical Neurology
Enrique Martinez-Pias, David Garcia-Azorin, Ane Minguez-Olaondo, Javier Trigo, Alvaro Sierra, Marina Ruiz, Angel L. Guerrero
Summary: The study found that three-quarters of chronic migraine patients did not use triptans, and nonuse of triptans was not solely due to tolerability, frequency of contraindications, or vascular risk factors. Triptan users consumed symptomatic medications fewer days per month, were under prophylactic treatment more frequently, and had medication overuse headache less frequently compared to triptan naive patients.
EXPERT REVIEW OF NEUROTHERAPEUTICS
(2021)